Abbott's TriCor Off-Label, Kickback Settlement Is Fraction of 2012 Agreement
$25m settlement resolves allegations covering 2006-2008 period; Abbott inked $1.5bn settlement with government six years ago involving Depakote promotion. This is DOJ's fourth pharma deal of the year.
You may also be interested in...
Agreement with New York attorney general resolves allegations Pfizer deceptively advertised that consumers would "pay no more" than $15 or $20 for drugs even though they were often far more expensive.
Corporate integrity agreement attached to second DOJ settlement over repackaging of injectable cancer drugs would require recoupment of exec performance pay following misconduct.
While DOJ probes have declined in last few years, 13 of top 25 pharma companies are dealing with ongoing inquiries of marketing and pricing practices.